Mucus production is a relevant pathophysiological picture of CB and COPD and is associated with worse healthcare outcomes and an increased rate of exacerbations. Overall, results from clinical studies ...
Early identification and treatment of patients with COPD at risk of exacerbation are crucial for better outcomes. Single-inhaler triple therapy (SITT) users showed improved exacerbation rates and ...
COPD may originate from chronic bronchitis, which inflames the airways, or from emphysema, which damages the lung air sacs. Key indicators of COPD may include persistent breathing changes such as ...
Singapore Business Review on MSN
65LAB backs NUS biotech venture with $2.13m funding
The capital will help advance a treatment candidate for a chronic lung disease. Singapore-based venture creation platform 65LAB has committed $2.13m (US$1.66m) to a National University of Singapore ...
COPD is a progressive lung disease with mild symptoms in the early stages that gradually worsen. Early diagnosis and treatment can help preserve lung function. The GOLD system previously classified ...
Digital therapeutics firm Kaia Health is partnering with Italian pharma firm Chiesi Group to commercialise its chronic obstructive pulmonary disease (COPD) rehabilitation app in Europe. The Kaia COPD ...
The free sulfhydryl group of metabolite I breaks the disulfide bridges of mucus glycoproteins, resulting in reduced sputum physical properties in patients with acute and chronic mucus hypersecretion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results